Điều Trị Virus Viêm Gan C Trong Các Bệnh Nhân Mắc Bệnh Xơ Gan Không Bù Đắp

Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–17. https://doi.org/10.1056/NEJMoa1009482. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206. https://doi.org/10.1056/NEJMoa1010494. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009;360(18):1839–50. https://doi.org/10.1056/NEJMoa0807650. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827–38. https://doi.org/10.1056/NEJMoa0806104. Flamm S. How to treat patients with chronic hepatitis C virus infection and decompensated cirrhosis. Curr Hepatol Rep. 2016;15:60–6. https://doi.org/10.1007/s11901-016-0291-0. Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post-transplantation. J Hepatol. 2014;61(1 Suppl):S120–31. https://doi.org/10.1016/j.jhep.2014.07.020. Lawitz E, Rodriguez-Torres M, Cornpropst M, et al. The effect of hepatic impairment on the pharmacokinetics and antiviral activity of PSI-7977 in hepatitis C infected subjects treated for seven days. abstract. J Hepatol. 2012;56(Supplement 2):S445–446. Kwo P, Agrawal S. Treating hepatitis C virus in patients with decompensated cirrhosis: why is it so difficult and does a sustained response rate rescue the patient from liver transplantation? Clin Liver Dis (Hoboken). 2015;6(6):133–5. https://doi.org/10.1002/cld.519. • Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–59. doi:https://doi.org/10.1053/j.gastro.2015.05.010. The SOLAR-1 trial in the USA demonstrated safety/efficacy of sofosbuvir-ledipasvir for HCV genotypes 1 and 4 including in decompensated cirrhosis, prior liver transplantation, and recurrent HCV. • Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–697. doi:https://doi.org/10.1016/S1473-3099(16)00052-9. Similar to the SOLAR-1, the SOLAR-2 trial also demonstrated the efficacy and safety of sofosbuvir-ledipasvir for HCV genotypes 1 and 4, but this was a larger, multi-continental trial. Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of ledipasvir-sofosbuvir combination in patients with hepatitis C virus infection and factors associated with sustained virologic response. Gastroenterology. 2016;151(6):1131–1140 e5. doi:https://doi.org/10.1053/j.gastro.2016.08.004 Foster GR, Irving WL, Cheung MC, et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol. 2016;64(6):1224–31. https://doi.org/10.1016/j.jhep.2016.01.029. • Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–28. doi:https://doi.org/10.1056/NEJMoa1512614. The ASTRAL-4 trial established the safety and efficacy of the pan-genotypic, fixed dose sofosbuvir-velpatasvir for use in patients with decompensated cirrhosis, including those with prior interferon-treatment. Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenterol. 2019;54(1):87–95. https://doi.org/10.1007/s00535-018-1503-x. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science. 1972;177(4050):705–6. https://doi.org/10.1126/science.177.4050.705. Mathur P, Kottilil S, Wilson E. Use of ribavirin for hepatitis C treatment in the modern direct-acting antiviral era. J Clin Transl Hepatol. 2018;6(4):431–7. https://doi.org/10.14218/JCTH.2018.00007. Koh C, Liang TJ. What is the future of ribavirin therapy for hepatitis C? Antiviral Res. 2014;104:34–9. https://doi.org/10.1016/j.antiviral.2014.01.005. Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM. Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int. 2017;37(1):5–18. https://doi.org/10.1111/liv.13212. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–82. https://doi.org/10.1056/NEJMoa020047. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485–92. doi:https://doi.org/10.1056/NEJM199811193392101 HCV guidance: recommendations for testing, managing, and treating hepatitis C. Accessed October 1, 2020, HCVguidelines.org Ribavirin prescribing information. Accessed October 1, 2020, https://www.drugs.com/pro/ribavirin.html Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74. doi:https://doi.org/10.1002/hep.22759 Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9(6):509–516 e1. doi:https://doi.org/10.1016/j.cgh.2011.03.004 Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52(3):833–44. https://doi.org/10.1002/hep.23744. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93. https://doi.org/10.1001/jama.2012.144878. Flemming JA, Kim WR, Brosgart CL, Terrault NA. Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy. Hepatology. 2017;65(3):804–12. https://doi.org/10.1002/hep.28923. Bunchorntavakul C, Reddy KR. Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J Viral Hepat. 2016;23(6):408–18. https://doi.org/10.1111/jvh.12534. Ekpanyapong S, Reddy KR. Hepatitis C virus therapy in advanced liver disease: outcomes and challenges. United European Gastroenterol J. 2019;7(5):642–50. https://doi.org/10.1177/2050640619840149. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016;65(3):524–31. https://doi.org/10.1016/j.jhep.2016.05.010. Belli LS, Duvoux C, Berenguer M, et al. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. J Hepatol. 2017;67(3):585–602. https://doi.org/10.1016/j.jhep.2017.03.006. Tapper EB, Hughes MS, Buti M, et al. The optimal timing of hepatitis C therapy in transplant eligible patients with child B and C cirrhosis: a cost-effectiveness analysis. Transplantation. 2017;101(5):987–95. https://doi.org/10.1097/TP.0000000000001400. Lawitz E, Landis C, Maliakkal B. Safety and efficacy of treatment with once daily ledipasvir/sofobuvir (90/400 mg) for 12 weeks in genotype 1 HCV infected patients with severe renal impairment. 2017: Gaur N, Malhotra V, Agrawal D, et al. Sofosbuvir-velpatasvir fixed drug combination for the treatment of chronic hepatitis C infection in patients with end-stage renal disease and kidney transplantation. J Clin Exp Hepatol. 2020;10(3):189–93. https://doi.org/10.1016/j.jceh.2019.10.004. Borgia S, Dearden J, Yoshida EM. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;pii(19)(S0168–8278):30343–5. Li M, Chen J, Fang Z, Li Y, Lin Q. Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4–5 chronic kidney disease: a systematic review and meta-analysis. Virol J. 2019;16(1):34. https://doi.org/10.1186/s12985-019-1140-x. Hernandez MD, Sherman KE. HIV/hepatitis C coinfection natural history and disease progression. Curr Opin HIV AIDS. 2011;6(6):478–82. https://doi.org/10.1097/COH.0b013e32834bd365. Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol. 2009;83(15):7366–74. https://doi.org/10.1128/JVI.00191-09. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23(4):512–20. https://doi.org/10.1111/j.1440-1746.2008.05384.x. Mavilia MG, Wu GY. HBV-HCV coinfection: viral interactions, management, and viral reactivation. J Clin Transl Hepatol. 2018;6(3):296–305. https://doi.org/10.14218/JCTH.2018.00016. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. Accessed October 1, 2020, https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-about-risk-hepatitis-b-reactivating-some-patients-treated Yen YH, Chen CH, Hung CH, et al. Active hepatocellular carcinoma is an independent risk factor of direct-acting antiviral treatment failure: a retrospective study with prospectively collected data. PLoS ONE. 2019;14(10):e0222605. https://doi.org/10.1371/journal.pone.0222605. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. J Hepatol. 2017;67(1):32–9. https://doi.org/10.1016/j.jhep.2017.02.027. Prenner SB, VanWagner LB, Flamm SL, Salem R, Lewandowski RJ, Kulik L. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66(6):1173–81. https://doi.org/10.1016/j.jhep.2017.01.020. Faria LC, Gigou M, Roque-Afonso AM, et al. Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. Gastroenterology. 2008;134(7):1890–9; quiz 2155. doi:https://doi.org/10.1053/j.gastro.2008.02.064 Riaz A, Awais R, Salem R. Side effects of yttrium-90 radioembolization. Front Oncol. 2014;4:198. https://doi.org/10.3389/fonc.2014.00198. Radhakrishnan K, Di Bisceglie AM, Reddy KR, et al. Treatment status of hepatocellular carcinoma does not influence rates of sustained virologic response: an HCV-TARGET analysis. Hepatol Commun. 2019;3(10):1388–99. https://doi.org/10.1002/hep4.1412. Marrero JA, Singal AG. Direct-acting antivirals and recurrence of hepatocellular carcinoma. Liver Transpl. 2017;23(9):1099–100. https://doi.org/10.1002/lt.24822. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358–80. https://doi.org/10.1002/hep.29086. Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. Am J Transplant. 2017;17(11):2790–2802. doi:https://doi.org/10.1111/ajt.14381 Nilles K, Flamm S. The use of grafts from HCV+ patients in transplantation: are we there yet? Curr Hepatol Rep. 2019;18:233–41. https://doi.org/10.1007/s11901-019-00466-0.